Aβ-Lowering Drug Verubecestat NOT Effective in Alzheimer’s, NEJM RCT

A phase 3 clinical trial of verubecestat, a β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) inhibitor, did not demonstrate improvement in cognitive outcomes or slowing of functional decline in patients with Alzheimer’s disease.  Verubecestat thus joins a long line of unsuccessful pharmacological therapies aimed at slowing the progression of Alzheimer’s disease.

 

Original Article from The New England Journal of Medicine — Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

Source: Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease | NEJM

Advertisements